Pharma, Biotech and Generics Industry News | The Pharmaletter
网页Pharmaceutical. BRIEF—ABPI reviews first six months of the 2024 Voluntary Scheme. The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year.4 October 2024. Biotechnology. BRIEF—Sirnaomics secures $7.5 million in share subscription.
Pharmaceutical Industry News | The Pharmaletter
网页2024年9月24日 · Mergers and Acquisitions. The Pharma Letter M&A roundup - September 2024. Pharma dealmakers appear to have largely remained on their summer holidays in a month when none of the industry's biggest players announced acquisitions.2 October 2024. M&A activity – new inflammatory disease targets …
About The Pharma Letter | The Pharmaletter
网页4 天之前 · The Pharma Letter offers high value news and insights for people with a professional interest in the global pharmaceutical, biotech, generic and biosimilar industries. Headquartered in London, the company draws from a network of foreign correspondents, with healthcare journalists around the world providing insight on local markets.
Login - The Pharmaletter
网页3 天之前 · The Pharma Letter. 39-43 Putney High Street, Putney London, SW15 1SP United Kingdom
Pharmaceutical Generics Industry News | The Pharmaletter
网页2024年9月2日 · Glenmark pays $25 million fine for generic price-fixing. Glenmark Pharmaceuticals has agreed to pay $25 million, based on its ability to pay, to resolve its alleged liability under the False Claims Act for conspiring to fix the price of a generic drug, the US Department of Justice announced. 5 September 2024.
ESMO 2024: What’s coming up? - The Pharmaletter
网页2024年9月10日 · The ESMO Congress 2024 will showcase a wealth of new oncology data, highlighting the pace of innovation in cancer treatment. Key presentations include: Merck KGaA: New insights on a first-in-class ADC for CEACAM5-overexpressing tumors and DDR inhibitors for advanced solid tumors, with encouraging activity observed, especially in BRCA1-mutated tumors.
Subscribe to The Pharma Letter | The Pharmaletter
网页3 天之前 · The Pharma Letter. 39-43 Putney High Street, Putney London, SW15 1SP United Kingdom
FDA accepts Vertex’ suzetrigine NDA for priority review
网页2024年7月31日 · The US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submission for suzetrigine (VX-548), an investigational, oral, selective NaV1.8 pain signal inhibitor to treat moderate-to-severe acute pain.
USA Clears Ivermectin For Human Use - The Pharma Letter
网页1996年12月2日 · USA Clears Ivermectin For Human Use. 2 December 1996. In the USA, the Food and Drug Administration has approved Merck & Co's Stromectil (ivermectin) for its first non-veterinary use, the chemotherapy of two parasitic infections, strongyloidiasis and onchocerciasis, in humans. Ivermectin has been used …
Curve Therapeutics | The Pharmaletter
网页6 天之前 · Curve Therapeutics. A biotech company developing an intracellular screening platform addressing complex and challenging disease targets. Curve originated from Microcycle research conducted by Professor Tavassoli’s group in the Department of Chemistry at the University of Southampton, UK. The company is backed by Advent Life Sciences, Epidarex ...